Novel Tryptamine Compounds as 5-HT2A Agonists for Treating Mood Disorders such as Depressive Disorders and Bipolar Disorders.
Ram W. Sabnis, Anika R. Sabnis
ACS Med Chem Lett February 13, 2025 DOI: 10.1021/acsmedchemlett.5c00047 (opens in new tab) via PubMed Central
Summary
AI-generated from the abstractThe text describes novel tryptamine compounds that act as agonists at the 5-HT2A receptor, a serotonin receptor subtype, for potential treatment of mood disorders including depressive disorders and bipolar disorders. The work presents these compounds as a therapeutic approach, but no specific findings, experimental results, or clinical data are reported.
Study at a glance
| Characteristics | Theoretical or philosophical paper Peer reviewed |
|---|---|
| Intervention | novel tryptamine compounds |
| Key finding | Proposes that novel tryptamine compounds acting as 5-HT2A agonists could be developed for treating mood disorders such as depressive disorders and bipolar disorders. |
Abstract
Novel Tryptamine Compounds as 5-HT2A Agonists for Treating Mood Disorders such as Depressive Disorders and Bipolar Disorders.